Plaque PsoriasisPhase 3ONWARD2NCT06588738
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
A Phase 3 study testing Envudeucitinib and Apremilast in people with Plaque Psoriasis, run by Alumis Inc at 124 sites in 12 countries.
Trial summary
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Plaque Psoriasis
- What is being tested?
- Envudeucitinib and Apremilast
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 862 participants
- Where
- 124 sitesin 12 countries
- Study dates
- 20 Aug 2024to 18 Dec 2025
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males or females, age ≥18 years
- Diagnosis of plaque psoriasis for ≥6 months
- Plaques covering ≥10% of BSA
- PASI ≥12
- sPGA ≥3
- Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception
Who cannot join
- Nonplaque psoriasis or other inflammatory skin conditions
- Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate
- Pregnant, lactating, or planning to get pregnant during the study
- Use of drugs prior to Study Day 1 that treat or may affect psoriasis:
- Topical within 2 weeks
- Phototherapy or any systemic treatments within 4 weeks
Show all 21Show fewer
- Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months
- Systemic immunosuppressants or immunomodulatory drugs within 4 weeks
- Modulators of B cells within 6 months, or T cells within 3 months
- JAK inhibitors or TYK2 inhibitors within 4 weeks
- PDE4 inhibitor within 2 months
- Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study
- Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment
- Patients with QTcF >450 msec (males) or >470 msec (females) at Screening
- Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months
- Evidence of recent or recurrent herpes zoster or herpes simplex viral infection
- Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB
- History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment
- Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status
- Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction
- History of any immune-mediated or inflammatory medical condition for which patient requires current systemic corticosteroids
Trial locations and contacts
124 sites in 12 countries.
124 sites in 12 countries
United States43 sites
Asheville Clinical Trials
Asheville, North Carolina, 28803
Zenith Research Inc.
Beverly Hills, California, 90211-1705
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, 35203
Optima Research Boardman
Boardman, Ohio, 44512
Chandler Clinical Trials
Chandler, Arizona, 85224
Michigan Center for Research Company
Clarkston, Michigan, 48346
DS Research of Southern Indiana
Clarksville, Indiana, 47129
Modern Research Associates PLLC
Dallas, Texas, 75231
Henry Ford Medical Center - Farmington Road
Detroit, Michigan, 48202
NYC Health and Hospitals Elmhurst
Elmhurst, New York, 11373
Raoof MD
Encino, California, 91436
FXM Clinical Research Ft. Lauderdale LLC
Fort Lauderdale, Florida, 33308
Direct Helpers Research Center (DHRC)
Hialeah, Florida, 33012
Clinical Partners LLC
Johnston, Rhode Island, 02919
Las Vegas Clinical Trials
Las Vegas, Nevada, 89030
Long Beach Research Institute
Long Beach, California, 90805
Dermatology Research Associates
Los Angeles, California, 90045
DS Research of Kentucky
Louisville, Kentucky, 40241
SMS Clinical Research
Mesquite, Texas, 75149
AppleMed Research Group under WCG
Miami, Florida, 33126
FAX Pharma Clinical Research Inc
Miami, Florida, 33146
FXM Clinical Research - Miami LLC
Miami, Florida, 33175
Las Mercedes Medical Research
Miami, Florida, 33196
FXM Clinical Research Miramar LLC
Miramar, Florida, 33027
Associated Skin Care Specialists - Minnesota Clinical Study Center
New Brighton, Minnesota, 55112
Pioneer Clinical Research NY
New York, New York, 10016
Cameron Dermatology
New York, New York, 10023
Renstar Medical Research
Ocala, Florida, 34470
Schlessinger MD
Omaha, Nebraska, 68144
The Indiana Clinical Trials Center
Plainfield, Indiana, 46168
Empire Clinical Research - Pomona
Pomona, California, 91767
Integrative Skin Science and Research
Sacramento, California, 95815
Progressive Clinical Research - San Antonio
San Antonio, Texas, 78213
UC San Diego
San Diego, California, 92122
Southern California Clinical Research
Santa Ana, California, 92701
Clinical Science Institute Dermatology Institute
Santa Monica, California, 90404
Jordan Valley Dermatology
South Jordan, Utah, 84095
DermResearchCenter of New York
Stony Brook, New York, 11790
Revival Research Institute
Troy, Michigan, 48084
Noble Clinical Research
Tucson, Arizona, 85704
Grekin Skin Institute
Warren, Michigan, 48088
Center for Clinical Studies (CCS) - Webster/Clear Lake Location
Webster, Texas, 77598
WDC Cosmetic and Research
Wilmington, North Carolina, 28405
Poland18 sites
Specderm
Bialystok, Podlaskie Voivodeship, 15-375
Pratia Gdynia
Gdynia, Pomeranian Voivodeship, 81-338
Pratia Katowice
Katowice, Silesian Voivodeship, 40-018
Research Solutions
Katowice, Silesian Voivodeship, 40-748
Care Clinic Katowice
Katowice, 40-568
FutureMeds Krakow
Krakow, Lesser Poland Voivodeship, 31-501
Centrum Medyczne dr Rajzer Spolka Zoo
Krakow, Malopolska, 30-438
Dermoklinika
Lodz, Łódź Voivodeship, 90-436
FutureMeds Lodz
Lodz, Łódź Voivodeship, 91-363
Luxderm
Lublin, 20-573
Zanamed Medical Clinic Sp z o o
Lublin, 20-601
Klinika Dermatologii Uniwersytecki Szpital Kliniczny im F Chopina
Rzeszów, Podkarpackie Voivodeship, 50-368
RCMed Oddział Sochaczew
Sochaczew, Masovian Voivodeship, 96-500
Clinical Best Solutions
Warsaw, Masovian Voivodeship, 00-710
Centrum Medyczne Evimed
Warsaw, Masovian Voivodeship, 02-625
MTZ Clinical Research Sp z o o
Warsaw, 02-172
Klinika Ambroziak Dermatologia Kliniczna
Warsaw, 02-953
dermMedica
Wroclaw, 51-503
Canada17 sites
CCA Medical Research Corp
Ajax, Ontario, L1S 7K8
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, L4M 7G1
Beacon Dermatology
Calgary, Alberta, T3E 0B2
SKiN Health
Cobourg, Ontario, K9A 0Z4
Alberta DermaSurgery
Edmonton, Alberta, T6G 1C3
VIDA Dermatology/VIDA Clinical Research
Edmonton, Alberta, T6H 4J8
Guelph Dermatology Research
Guelph, Ontario, N1L 0B3
Mediprobe Research
London, Ontario, N5X 2P1
Innovaderm
Montreal, Quebec, H2X 2V1
Clear Skin Dermatology
Newmarket, Ontario, L3Y 5G8
North Bay Dermatology Centre
North Bay, Ontario, P1B 3Z7
Rejuvination Dermatology Oakville
Oakville, Ontario, L6H 6P8
CaRe Clinic Red Deer
Red Deer, Alberta, T4P 1K4
SkinSense Medical Research
Saskatoon, Saskatchewan, S7K 2C1
Skincare Studio
St. John's, Newfoundland and Labrador, A1E 1V4
Toronto Research Centre
Toronto, Ontario, M3H 5Y8
XLR8 Medical Research
Windsor, Ontario, N8T 1E6
Germany13 sites
ISA - Interdisciplinary Study Association GmbH
Berlin, 10789
Hautarztpraxis Dr Niesmann and Dr Othlinghaus
Bochum, North Rhine-Westphalia, 44793
Rosenpark Research
Darmstadt, Hesse, 64283
Praxis fur Dermatologie und Venerologie
Dresden, Saxony, 01097
Klinische Forschung Dresden GmbH
Dresden, Saxony, 1069
Universitatsklinikum Erlangen
Erlangen, Bavaria, 91054
MVZ DermaKiel GmbH
Kiel, D-24148
Haut Ambulatorium Magdeburg
Magdeburg, 39104
Dermatologische Praxis Dres Quist
Mainz, Rhinelkand-Palatinate, 55128
Universitaetsklinikum Muenster
Münster, North Rhine-Westphalia, 48149
Klinikum Oldenburg
Oldenburg, Lower Saxony, 26133
KliFOs Klinische Forschung Osnabruck
Osnabrück, 49074
Klinische Forschung Schwerin GmbH
Schwerin, Mecklenburg-Vorpommern, 19055
Hungary8 sites
DermaMed Research Kf
Békés, Oroshaza, 5900
Uno Medical Trials Kft
Budapest, 1152
Borgyogyaszati Klinika Debreceni Egyetem Orvos es Egeszsegtudomenyi Centrum
Debrecen, Hajdú-Bihar, 4032
DERMA B Kft
Debrecen, Hajdú-Bihar Megye, 4031
Orvostudomanyi Kutato es Fejleszto Kft
Debrecen, 4027
Bacs Kiskun County Teaching Hospital
Kecskemét, Bács-Kiskun county, 6000
Allergo Derm Bakos Kft
Szolnok, 5000
Medmare Bt
Veszprém, 8200
Latvia7 sites
Semigallia Ltd
Kuldīga, Kuldigas, LV3301
Riga 1st Hospital
Riga, LV1001
Med Art Clinic
Riga, LV1003
Veselibas Centrs 4
Riga, LV1003
SIA Veseliba un estetika
Riga, LV1009
Veselibas Centrs 4 Filiale Dermatologijas Klinika
Riga, LV1013
Smite Aija Medical Practice in Dermatology Venereology
Talsi, LV3201
Spain5 sites
University General Hospital Dr Balmis
Alicante, 3010
Hospital de la Santa Creu i Sant Pau
Barcelona, 8041
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital de Manises
Manises, 46940
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, 15706
Estonia4 sites
Innomedica
Tallinn, Harju, 10117
Center for Clinical and Basic Research AS
Tallinn, 10128
Tartu University Hospital
Tartu, Tartu, 50411
Kliiniliste Uuringute Keskus OU
Tartu, 50106
Puerto Rico4 sites
Centro Reumatologico de Caguas
Caguas, 00725
Ponce Medical School Foundation Inc
Ponce, 00716
Clinical Research Puerto Rico
Ponce, 00909
GCM Medical Group PSC Hato Rey Site
San Juan, PR, 00917
France3 sites
Centre Azur Nice
Nice, 06000
Polyclinique de Courlancy
Reims, 51100
CHU de Rouen
Rouen, Normandy, 76031
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:
- Does ESK-001 reduce the severity of people's psoriasis?
- How safe is ESK-001 in people with moderate to severe plaque psoriasis?
Read more
The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).
People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe.
Participants will:
- take drug every day for 24 weeks.
- visit the clinic for checkups and tests.
- fill out questionnaires about their psoriasis, itch severity, and change in quality of life.
- be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health.
- provide blood and urine samples.
- Conditions
- Plaque Psoriasis
- Being tested
- Envudeucitinib, Placebo, Apremilast
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EnvudeucitinibDrug
ESK-001
PlaceboDrug
Placebo
ApremilastDrug
Apremilast
| Study group | Role | What they receive |
|---|---|---|
| ESK-001 | Experimental | ESK-001 administered as an oral tablet Receives: Drug: Envudeucitinib |
| Placebo | Placebo comparator | Matching oral placebo Receives: Drug: Placebo |
| Apremilast | Active comparator | Apremilast administered as an oral capsule Receives: Drug: Apremilast |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo
Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA.
Measured: 16 weeks
Secondary outcomes (10)
To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast
Proportion of patients achieving of ≥90% or 100% reduction in PASI
Measured: 24 weeks
To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast
Proportion of patients achieving of ≥75% reduction in PASI
Measured: 24 weeks
To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast
Proportion of patients achieving a score of 0 or 1 on sPGA
Measured: 24 weeks
To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast
Change from baseline in %BSA
Measured: 24 weeks
To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast
Proportion of patients achieving a score of 0 or 1 on ssPGA
Measured: 24 weeks
To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast
Proportion of patients achieving a score of 0
Measured: 24 weeks
To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast
Proportion of patients achieving a score of 0 or 1
Measured: 24 weeks
To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo
Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).
Measured: 24 weeks
Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured: 24 weeks
To characterize the pharmacokinetics of ESK-001
Maximum [Cmax] and minimum [Cmin] plasma concentration
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start20 Aug 2024
- Primary completion23 Sep 2025
- Study completion18 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plaque PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 862 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alumis Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06588738
- Sponsor's protocol ID
- ESK-001-017
- Acronym
- ONWARD2
- Status last verified
- Oct 2026
- First submitted
- 7 Sep 2024
- Last updated
- 28 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
- ClinicalTrials.gov ID
- NCT06588738
- Acronym / sponsor ID
- ONWARD2 / ESK-001-017
- Conditions
- Plaque Psoriasis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 862 participants (actual)
- Lead sponsor
- Alumis IncIndustry (pharma, biotech, devices)
- Study start
- 20 Aug 2024 (actual)
- Primary completion
- 23 Sep 2025 (actual)
- Study completion
- 18 Dec 2025 (actual)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:
- Does ESK-001 reduce the severity of people's psoriasis?
- How safe is ESK-001 in people with moderate to severe plaque psoriasis?
The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).
People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe.
Participants will:
- take drug every day for 24 weeks.
- visit the clinic for checkups and tests.
- fill out questionnaires about their psoriasis, itch severity, and change in quality of life.
- be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health.
- provide blood and urine samples.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ESK-001 | Experimental | Drug: EnvudeucitinibESK-001 administered as an oral tablet |
| Placebo | Placebo comparator | Drug: PlaceboMatching oral placebo |
| Apremilast | Active comparator | Drug: ApremilastApremilast administered as an oral capsule |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Males or females, age ≥18 years
- Diagnosis of plaque psoriasis for ≥6 months
- Plaques covering ≥10% of BSA
- PASI ≥12
- sPGA ≥3
Key exclusion criteria (21 listed)
- Nonplaque psoriasis or other inflammatory skin conditions
- Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate
- Pregnant, lactating, or planning to get pregnant during the study
- Use of drugs prior to Study Day 1 that treat or may affect psoriasis:
- Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EnvudeucitinibESK-001 | Drug | ESK-001 |
| PlaceboPlacebo | Drug | Placebo |
| ApremilastApremilast | Drug | Apremilast |
Primary outcome
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo
Time frame: 16 weeks
Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA.
10 secondary outcomes
To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast
Time frame: 24 weeks
To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast
Time frame: 24 weeks
To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast
Time frame: 24 weeks
To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast
Time frame: 24 weeks
To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast
Time frame: 24 weeks
To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast
Time frame: 24 weeks
To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast
Time frame: 24 weeks
To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo
Time frame: 24 weeks
Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 24 weeks
To characterize the pharmacokinetics of ESK-001
Time frame: 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: Undecided. The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.
Related trials for Plaque Psoriasis
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar Psoriasis
RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Psoriasis, Overweight or Obesity
Active, not recruitingPhase 3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
124 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Envudeucitinib and Apremilast in people with Plaque Psoriasis, run by Alumis Inc at 124 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 124 sites in United States, Poland, Canada, Germany, Hungary and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (time frame: 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.